Ayala Pharmaceuticals, Inc. filed its 10-K on Mar 31, 2023 for the period ending Dec 31, 2022. In this report its auditor, Kost Forer Gabbay & Kasierer, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2625 USD | +4.96% |
|
-7.47% | -60.64% |
![Consensus](/images/consensus_flch.gif)
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-60.64% | 10.66M | |
+35.15% | 51.07B | |
-7.64% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+12.10% | 26.35B | |
-17.48% | 19.46B | |
+41.33% | 13.58B | |
+31.04% | 12.46B | |
-2.99% | 11.75B |
- Stock Market
- Equities
- ADXS Stock
- News Ayala Pharmaceuticals, Inc.
- Ayala Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt